Rare Case Report of Primary Active Pulmonary Tuberculosis During Ixekizumab Treatment for Plaque Psoriasis

IF 2.2 4区医学 Q3 DERMATOLOGY Clinical, Cosmetic and Investigational Dermatology Pub Date : 2024-07-31 DOI:10.2147/ccid.s475486

Yuan Li, Jiejie Lu, Jingqiu Fu

{"title":"Rare Case Report of Primary Active Pulmonary Tuberculosis During Ixekizumab Treatment for Plaque Psoriasis","authors":"Yuan Li, Jiejie Lu, Jingqiu Fu","doi":"10.2147/ccid.s475486","DOIUrl":null,"url":null,"abstract":"Abstract: Biologic agents have become a mainstay in the treatment of psoriasis, particularly in moderate to severe, refractory, and special types of the disease. Among these, ixekizumab is a humanized IgG4 monoclonal antibody targeting interleukin-17A, approved for the treatment of moderate to severe plaque psoriasis. Its adverse effects include infections such as nasopharyngitis, upper respiratory tract infections, and injection site reactions. While the incidence of tuberculosis (TB) associated with IL-17A antagonists is extremely low, this paper reports a case of active pulmonary tuberculosis occurring after ten doses of ixekizumab treatment for chronic plaque psoriasis. This highlights the importance for clinicians to remain vigilant regarding tuberculosis infection in patients undergoing therapy with this class of medications, emphasizing the need for enhanced screening and monitoring for tuberculosis during treatment. Keywords: interleukin-17A antagonists, ixekizumab, psoriasis, primary active pulmonary tuberculosis ","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"48 1","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical, Cosmetic and Investigational Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/ccid.s475486","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract: Biologic agents have become a mainstay in the treatment of psoriasis, particularly in moderate to severe, refractory, and special types of the disease. Among these, ixekizumab is a humanized IgG4 monoclonal antibody targeting interleukin-17A, approved for the treatment of moderate to severe plaque psoriasis. Its adverse effects include infections such as nasopharyngitis, upper respiratory tract infections, and injection site reactions. While the incidence of tuberculosis (TB) associated with IL-17A antagonists is extremely low, this paper reports a case of active pulmonary tuberculosis occurring after ten doses of ixekizumab treatment for chronic plaque psoriasis. This highlights the importance for clinicians to remain vigilant regarding tuberculosis infection in patients undergoing therapy with this class of medications, emphasizing the need for enhanced screening and monitoring for tuberculosis during treatment.

Keywords: interleukin-17A antagonists, ixekizumab, psoriasis, primary active pulmonary tuberculosis

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

伊克珠单抗治疗斑块状银屑病期间原发性活动性肺结核罕见病例报告

摘要：生物制剂已成为治疗银屑病，尤其是中重度、难治性和特殊类型银屑病的主要药物。其中，ixekizumab 是一种靶向白细胞介素-17A 的人源化 IgG4 单克隆抗体，已被批准用于治疗中度至重度斑块状银屑病。其不良反应包括鼻咽炎、上呼吸道感染和注射部位反应等感染。虽然与IL-17A拮抗剂相关的肺结核（TB）发病率极低，但本文报道了一例慢性斑块状银屑病患者在接受10次ixekizumab治疗后发生活动性肺结核的病例。这凸显了临床医生对接受该类药物治疗的患者保持结核感染警惕的重要性，强调了在治疗期间加强结核筛查和监测的必要性。关键词：白细胞介素-17A拮抗剂；ixekizumab；银屑病；原发性活动性肺结核

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical, Cosmetic and Investigational Dermatology Medicine-Dermatology

CiteScore

2.80

自引率

4.30%

发文量

353

审稿时长

16 weeks

期刊介绍： Clinical, Cosmetic and Investigational Dermatology is an international, peer-reviewed, open access journal that focuses on the latest clinical and experimental research in all aspects of skin disease and cosmetic interventions. Normal and pathological processes in skin development and aging, their modification and treatment, as well as basic research into histology of dermal and dermal structures that provide clinical insights and potential treatment options are key topics for the journal. Patient satisfaction, preference, quality of life, compliance, persistence and their role in developing new management options to optimize outcomes for target conditions constitute major areas of interest. The journal is characterized by the rapid reporting of clinical studies, reviews and original research in skin research and skin care. All areas of dermatology will be covered; contributions will be welcomed from all clinicians and basic science researchers globally.